Relypsa's Veltassa OK'd, But Black Box Spooks Investors
This article was originally published in Scrip
Executive Summary
Even though Relypsa Inc. achieved the ultimate regulatory success of gaining US approval on Oct. 21 of Veltassa (patiromer) – the first drug in 50 years to treat hyperkalemia, which often affects people with stage 3 or 4 chronic kidney disease, heart failure, diabetes and hypertension – investors were spooked by the black-box warning the FDA imposed on the medicine's labeling.
You may also be interested in...
Garland Takes Helm Of Portola At A Crucial Time
Portola touts exec's commercial management experience with Genentech success stories Avastin and Tarceva.
Moderna's Valera Takes mRNA Approach To Combat Zika
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan's Price Reform Pledge: Will Others Follow?
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.